Company / Cash & Equivalents
BIOMERICA INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.4M
FY2025
5-year range
$2.4M / $9.7M
FY2021-FY2025
Trend
-42.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $686,785 in FY2019 to $10M in FY2023.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -22.6%.
Declined from $10M to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -26.0%
- 5-Year CAGR
- -22.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -22.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 42.5% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -42.5% |
| FY2024 | $4.2M | -57.1% |
| FY2023 | $9.7M | +64.3% |
| FY2022 | $5.9M | +40.9% |
| FY2021 | $4.2M | -51.4% |
| FY2020 | $8.6M | +1158.2% |
| FY2019 | $686.8K | -43.0% |
| FY2018 | $1.2M | -1.7% |
| FY2017 | $1.2M | -35.1% |
| FY2016 | $1.9M | +73.6% |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026